Albuterol Zionova
Last Updated: April 05, 2026
Lab Tested
Quality Assured
Fast Shipping
Secure Checkout
10
mg
50
Tablets
Albuterol by Zionova is a performance-focused bronchodilator designed for athletes, bodybuilders, and active individuals. Each bottle contains 50 tablets dosed at 10mg each, delivering fast and reliable support for breathing, endurance, and body composition.
Product Specifications
| Parameter | Detail |
|---|---|
| Product Name | Albuterol by Zionova |
| Tablets per Bottle | 50 |
| Dosage per Tablet | 10mg |
Key Features
Enhanced Breathing: Relaxes airways to improve oxygen flow during intense workouts and cardio sessions
Boosted Endurance: Improved oxygen delivery to muscles reduces fatigue and supports longer training sessions
Fat Loss and Muscle Preservation: Helps burn fat while maintaining lean muscle, ideal for cutting cycles
Fast-Acting Formula: Reliable and efficient action suited for pre-workout use
Consistent Dosing: Each tablet delivers a precise 10mg dose for easy integration into any routine
How to Use
Follow the recommended dosage and combine Albuterol with a balanced diet and structured workout program. Adjust intake based on your individual fitness level and goals.
Key Benefits
- Enhanced Breathing: Relaxes airways to improve oxygen flow during intense workouts and cardio sessions
- Boosted Endurance: Improved oxygen delivery to muscles reduces fatigue and supports longer training sessions
- Fat Loss and Muscle Preservation: Helps burn fat while maintaining lean muscle, ideal for cutting cycles
- Fast-Acting Formula: Reliable and efficient action suited for pre-workout use
- Consistent Dosing: Each tablet delivers a precise 10mg dose for easy integration into any routine
Who It Is For
Albuterol Zionova is well suited for men aged 18 to 55 focused on cardiovascular performance, cutting fat, or preserving muscle mass. It is particularly effective for athletes, bodybuilders, and anyone training for competition or pushing harder during regular sessions.
Reviews
There are no reviews yet.